About: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients Goto Sponge Distinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 2000

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 2000 (uk) im Juni 2000 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 2000 (ast) scientific article published on 01 June 2000 (en) գիտական հոդված հրատարակված 2000 թվականի հունիսի 1-ին (hy)
publication date	wds:Q73892792-05A11B55-A48F-4B6E-B51C-1EA3016AD331
publication date	2000-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q73892792-FB7085D4-FC02-4D96-BAC1-4A8C07CB77A9
language of work or name	English
author name string	wds:Q73892792-16F005F0-F2DA-4B31-B246-10BB798254E8 wds:Q73892792-2392C583-D8E9-44BC-AF9E-CC4CCF6E7753 wds:Q73892792-3303BB25-3FFF-447C-BBDF-4931664255F4 wds:Q73892792-3D7AEC88-47D0-4C95-81C9-1AE5C5810FA2 wds:Q73892792-5CFBB9B1-C9C1-4542-A501-D276F7CD11CE wds:Q73892792-9E7EFA57-EAD0-4C65-A91A-2AFEF808A2E6 wds:Q73892792-CCDC029C-89F0-4460-A76B-116062684F18 wds:Q73892792-E19F1AA6-52B4-4920-B409-F4F86BA49330
author name string	G Lombardi R Volpe R Pivonello F Di Salle A Di Sarno M L Landi S Cirillo F Scavuzzo
rdfs:label	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (en) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (nl)
skos:prefLabel	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (en) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (nl)
name	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (en) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (nl)
author	wds:Q73892792-4BF289FE-AB48-45B0-8908-64D4B91DEA25 wds:Q73892792-85B751BA-8321-4CAB-8D09-A22EF6DB6933 wds:Q73892792-FD9CDCDD-390E-4A7D-BCCB-5D7FFD16639F
author	Lucio Annunziato Annamaria Colao Paolo Cappabianca
title	wds:Q73892792-ED3CF6FB-78AF-4C07-BC81-AF8FBB334054
title	Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients (en)
page(s)	wds:Q73892792-BAAE77C9-3713-4280-885C-46F80AE08394
page(s)	2247-2252
instance of	wds:Q73892792-1384685A-8B01-48AD-A767-C8AD459C89F9
instance of	scholarly article
PubMed ID	wds:Q73892792-F4CB88BE-6C4C-4839-A727-37E4CF3E7955
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/10852458
PubMed ID	10852458
published in	wds:Q73892792-4C9D8F5F-4219-487B-BF57-95898DD4583C
published in	The Journal of Clinical Endocrinology and Metabolism
issue	wds:Q73892792-229909C7-8A39-4A62-B179-4CD32F1A291D
volume	wds:Q73892792-280194FE-C906-4C92-9D3D-A468B0791663
issue	6
volume	85
DOI	wds:Q73892792-E06B952A-C9DA-48A6-ABB7-B364B65804D1
DOI	http://dx.doi.org/10.1210/JCEM.85.6.6657
DOI	10.1210/JCEM.85.6.6657
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q73892792
is cites work of	Clinical pharmacokinetics of cabergoline Management of medically refractory prolactinoma Treatment of hyperprolactinemia: a systematic review and meta-analysis. Current management of prolactinomas Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status Medical therapy of pituitary adenomas: effects on tumor shrinkage Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas Pituitary apoplexy during therapy with cabergoline in an adolescent male with prolactin-secreting macroadenoma Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases Medical management of prolactin-secreting pituitary adenomas Medical treatment of prolactinomas Diagnosis and management of hyperprolactinemia: results of a Brazilian multicenter study with 1234 patients. Resistant prolactinomas Minor tumour shrinkage in nonfunctioning pituitary adenomas by long-term treatment with the dopamine agonist cabergoline Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis. Pharmacologic resistance in prolactinoma patients Management of aggressive pituitary adenomas: current treatment strategies Obstructive hydrocephalus and intracranial hypertension caused by a giant macroprolactinoma. Prompt response to medical treatment Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results Hyperprolactinemia in men: clinical and biochemical features and response to treatment Pharmacotherapy for adults with tumors of the central nervous system Treatment of hyperprolactinemia in post-menopausal women: pros Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging Dopamine resistance of prolactinomas Cabergoline versus bromocriptine for the treatment of giant prolactinomas: A quantitative and systematic review. A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Why and How? Management of macroprolactinomas Treatment of acromegaly: future Early prediction of long-term response to cabergoline in patients with macroprolactinomas Long-term management of prolactinomas--use of long-acting dopamine agonists Short-term pharmacological suppression of the hyperprolactinemia of infertile hCG-overproducing female mice persistently restores their fertility Management of prolactinomas in Brazil: an electronic survey Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience Prolactinomas Resistant to Treatment With Dopamine Agonists: Long-Term Follow-Up of Six Cases Multidisciplinary Management of Pituitary Apoplexy. Hyperprolactinaemia in male infertility: Clinical case scenarios. Functioning Pituitary Adenomas - Current Treatment Options and Emerging Medical Therapies Efficacy and safety of rapid escalation of cabergoline in comparison to conventional regimen for macroprolactinoma: A prospective, randomized trial Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis. Vanishing tumor in pregnancy

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software